Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anika TherapeuticsANIK -0.95%61 EV-to-EBITDA is 519.02 as of Sep. 08, 2026, which is 4413% above its 10-year median of 11.50. GuruFocus rates ANIK with a GF Score™ of 61/100 and a GF Value™ of $19.26 (Fairly Valued). The stock has 4 warning signs investors should review. Among 726 Drug Manufacturers companies, Anika Therapeutics ranks worse than 99.45% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Anika Therapeutics's enterprise value is $265.7 Mil.
Anika Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $0.5 Mil. Therefore, Anika Therapeutics's EV-to-EBITDA for today is 519.02.
The historical rank and industry rank for Anika Therapeutics's EV-to-EBITDA or its related term are showing as below:
ANIK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -568.28 Med: 11.5 Max: 557.8
Current: 519.02
During the past 13 years, the highest EV-to-EBITDA of Anika Therapeutics was 557.80. The lowest was -568.28. And the median was 11.50.
ANIK's EV-to-EBITDA is ranked worse than 99.45% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.75
vs ANIK: 519.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anika Therapeutics's PE Ratio (TTM) for today is calculated as:
Anika Therapeutics's share price for today is $20.84.
Anika Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Anika Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's EV-to-EBITDA falls into.
Anika Therapeutics's current Enterprise Value is $265.7 Mil.
Anika Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (ANIK) has a EV-to-EBITDA of 519.02 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anika Therapeutics. This is 4413% above median its historical median of 11.50. According to the industry distribution chart, Anika Therapeutics ranks #722 out of 726 companies in the Drug Manufacturers industry, placing it in the top 99.4%.
Is Anika Therapeutics' EV-to-EBITDA too high?
Anika Therapeutics' current EV-to-EBITDA of 519.02 is 4413% above median its 10-year median of 11.50. The Drug Manufacturers industry median EV-to-EBITDA is 13.75. Anika Therapeutics' value of 519.02 is 3674.7% above this industry median. Based on the distribution chart, Anika Therapeutics ranks #722 out of 726 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anika Therapeutics has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' EV-to-EBITDA compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #722 out of 726 companies for EV-to-EBITDA. This places Anika Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.75. Anika Therapeutics' value of 519.02 is 3674.7% above this benchmark. While the company's 10-year median is 11.50 vs. the industry median of 13.75, Anika Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.75, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anika Therapeutics's current EV-to-EBITDA of 519.02 is 3674.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anika Therapeutics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current EV-to-EBITDA is 519.02, which is 4413% above median its own 10-year median of 11.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Fairly Valued. The stock's GF Value™ is $19.26, compared to a current price of $20.84 — trading 8.2% above its estimated fair value. The current EV-to-EBITDA is 519.02, which is 4413% above median its 10-year median of 11.50 and 3674.7% above the Drug Manufacturers industry median of 13.75. Anika Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current EV-to-EBITDA is 519.02 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (ANIK) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued.
The current stock price of $20.84 is trading 8.2% above its estimated GF Value™ of $19.26.
GuruFocus considers Anika Therapeutics to be Fairly Valued.
Key valuation signals for ANIK:
EV-to-EBITDA: 519.02 (4413% above median its 10-year median of 11.50)
GF Value™: $19.26 vs. price of $20.84 (8.2% above fair value)
Industry Position: 3674.7% above the Drug Manufacturers median (#722 of 726)
No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
61GF Score
Get the complete analysis for ANIK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIK has been successfully added to your 
